My psychiatrist told me that he basically never prescribes this stuff because it doesn't improve concentration nearly as well as stimulants, and more importantly it has the same side effect profile as tricyclic antidepressants, e.g. tachycardia, orthostatic hypotension, urinary retention, cotton mouth. So these added warnings don't surprise me. It's amazing that the pharmaceutical industry can get docs to stop prescribing tricyclics because of the horrible side effects, but still manage sell drugs with indistinguishable side effects.

"None of which can be good news for Lilly and its drug".

The patent is probably about to expire anyway. They probably have a replacement in the works.

Hi,

Strattera was prescribed for my 11yo because I was adamant about not wanting her on stimulants due to a family history of alcoholism and addiction.

I stopped it after two weeks because she was miserably lethargic and nauseous. Since summer break was approaching I did not follow up on alternatives, but I may consider Adderall if she still has problems this coming school year.

I'm generally opposed to psychiatric/ADHD medications for children, but I finally relented after 7 years of trying dietary and behavioral changes.

In any event, I'm glad I found your blog as it appears to be a valuable source of information for consumers.

The patent doesn't expire until 2017. It's probably a win-win situation. By getting the information out now, Lilly won't be subject to a class action suit in the future and more hapless consumers won't be harmed.